Euroopan unioni - englanti - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - linaclotide - irritable bowel syndrome - drugs for constipation - constella is indicated for the symptomatic treatment of moderate to severe irritable-bowel syndrome with constipation (ibs-c) in adults.

Israel - englanti - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - sildenafil as citrate - film coated tablets - sildenafil as citrate 25 mg - sildenafil - sildenafil - treatment of erectile dysfunction.

Israel - englanti - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - sildenafil as citrate - film coated tablets - sildenafil as citrate 50 mg - sildenafil - sildenafil - treatment of erectile dysfunction.

Israel - englanti - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - sildenafil as citrate - film coated tablets - sildenafil as citrate 100 mg - sildenafil - sildenafil - treatment of erectile dysfunction.

Euroopan unioni - englanti - EMA (European Medicines Agency)

bayer ag - riociguat - hypertension, pulmonary - antihypertensives for pulmonary arterial hypertension - chronic thromboembolic pulmonary hypertension (cteph) adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah) adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. efficacy has been shown in a pah population including aetiologies of idiopathic or heritable pah or pah associated with connective tissue disease.

Yhdysvallat - englanti - NLM (National Library of Medicine)

general injectables & vaccines, inc - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 0.4 mg - nitrostat is indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. 4.1 pde-5-inhibitors and sgc-stimulators do not use nitrostat in patients who are taking pde-5 inhibitors, such as avanafil, sildenafil, tadalafil, vardenafil hydrochloride. concomitant use can cause severe hypotension, syncope, or myocardial ischemia [see drug interactions (7.1)]. do not use nitrostat in patients who are taking the soluble guanylate cyclase stimulators, such as riociguat. concomitant use can cause hypotension. 4.2 severe anemia nitrostat is contraindicated in patients with severe anemia (large doses of nitroglycerin may cause oxidation of hemoglobin to methemoglobin and could exacerbate anemia). 4.3 increased intracranial pressure nitrostat may precipitate or aggravate increased intracranial pressure and thus should not be used in patients with possible increased intracranial pressure (e.g., cerebral hemorrhage or traumatic brain injury). 4.4 hypersensitivity nitro

Yhdysvallat - englanti - NLM (National Library of Medicine)

merck sharp & dohme llc - vericiguat (unii: lv66adm269) (vericiguat - unii:lv66adm269) - verquvo® is indicated to reduce the risk of cardiovascular death and heart failure (hf) hospitalization following a hospitalization for heart failure or need for outpatient iv diuretics, in adults with symptomatic chronic hf and ejection fraction less than 45% [see clinical studies (14)] . verquvo is contraindicated in patients with concomitant use of other soluble guanylate cyclase (sgc) stimulators [see drug interactions (7.1)] . verquvo is contraindicated in pregnancy [see warnings and precautions (5.1) and use in specific populations (8.1)]. pregnancy surveillance program there is a pregnancy surveillance program that monitors pregnancy outcomes in women exposed to verquvo during pregnancy. health care providers should report any prenatal exposure to verquvo by calling 1-877-888-4231 or at https://pregnancyreporting.verquvo-us.com. risk summary based on data from animal reproduction studies, verquvo may cause fetal harm when administered to a pregnant woman and is contraindicated during pregnancy [see co

Euroopan unioni - englanti - EMA (European Medicines Agency)

bayer ag - vericiguat - heart failure - cardiac therapy - treatment of symptomatic chronic heart failure

Yhdysvallat - englanti - NLM (National Library of Medicine)

henry schein, inc. - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitrostat is indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. 4.1 pde-5-inhibitors and sgc-stimulators do not use nitrostat in patients who are taking pde-5 inhibitors, such as avanafil, sildenafil, tadalafil, vardenafil hydrochloride. concomitant use can cause severe hypotension, syncope, or myocardial ischemia [see drug interactions (7.1)]. do not use nitrostat in patients who are taking the soluble guanylate cyclase stimulators, such as riociguat. concomitant use can cause hypotension. 4.2 severe anemia nitrostat is contraindicated in patients with severe anemia (large doses of nitroglycerin may cause oxidation of hemoglobin to methemoglobin and could exacerbate anemia). 4.3 increased intracranial pressure nitrostat may precipitate or aggravate increased intracranial pressure and thus should not be used in patients with possible increased intracranial pressure (e.g., cerebral hemorrhage or traumatic brain injury). 4.4 hypersensitivity nitro

Australia - englanti - Department of Health (Therapeutic Goods Administration)

optimed pty ltd - 32729 - indirect binocular laser ophthalmoscope - the lion is a laser indirect ophthalmoscope where the laser source is built into the headset, eliminating the need for an external laser console. lion is controlled via a wireless tablet user interface utilizing a touch screen or voice control of parameters. lion is powered by a rechargeable battery built into the foot switch. the device may be used for all standard single-shot photocoagulation procedures